For more than 70 years, every antipsychotic medication on the market has worked by blocking dopamine receptors. That changed in September 2024 when the FDA approved Cobenfy, a combination of xanomeline and trospium chloride developed by Bristol Myers Squibb. It is the first entirely new class of schizophrenia medication in decades.
Why a New Mechanism Matters
Existing antipsychotics, both first-generation (typical) and second-generation (atypical), all target dopamine D2 receptors. While effective for many patients, dopamine-blocking drugs come with well-documented side effects: weight gain, metabolic syndrome, movement disorders like tardive dyskinesia, and sedation. These side effects cause a significant number of patients to stop taking their medication, which leads to relapse.
Cobenfy takes a fundamentally different approach. It works through muscarinic receptor modulation, specifically activating M1 and M4 muscarinic acetylcholine receptors. This pathway influences psychosis without directly blocking dopamine, which means the side effect profile looks different from traditional antipsychotics.
How Cobenfy Works
The drug is a combination of two compounds:
- Xanomeline is the active muscarinic agonist. It was originally studied as a potential Alzheimer's treatment in the 1990s but showed antipsychotic properties. The problem was that xanomeline alone caused significant gastrointestinal side effects, including nausea and vomiting.
- Trospium chloride is an anticholinergic agent that blocks peripheral muscarinic receptors. It counteracts the GI side effects of xanomeline without crossing the blood-brain barrier, so it does not interfere with xanomeline's therapeutic action in the brain.
This combination solved the tolerability problem that had stalled muscarinic-based treatments for years.
Clinical Trial Results
In Phase 3 trials, Cobenfy demonstrated statistically significant reductions in positive symptoms of schizophrenia (hallucinations, delusions) compared to placebo. Notably, it did not produce the weight gain, metabolic changes, or movement disorders commonly associated with dopamine-blocking antipsychotics.
The most common side effects reported were nausea, indigestion, and constipation, which are related to the muscarinic mechanism but were generally manageable.
A Bigger Year for Drug Approvals
Cobenfy was the standout, but 2024 was a productive year for the FDA overall. A total of 50 new drugs received approval, spanning a wide range of therapeutic areas. Some other notable approvals include:
- Exblifep, Zevtera, and Orlynvah. Three new antibiotics addressing serious bacterial infections, a category where new treatments have been desperately needed as antibiotic resistance continues to grow.
- Hympavzi and Alhemo. Two new treatments for hemophilia, offering patients additional options for managing a condition that requires lifelong therapy.
The breadth of approvals reflects continued investment in drug development across multiple disease areas, even as the pharmaceutical industry faces pricing pressures and regulatory scrutiny.
What This Means for Patients
Schizophrenia affects approximately 1% of the global population. In Canada, that translates to roughly 380,000 people. Many cycle through multiple antipsychotic medications trying to find one that controls symptoms without intolerable side effects. Cobenfy represents a genuinely new option, not just a reformulation or slight modification of an existing drug.
It is worth noting that Cobenfy has been approved by the FDA in the United States. Canadian approval through Health Canada follows its own review process and timeline. Patients in Canada should speak with their healthcare provider about when and whether Cobenfy may become available here.
The Significance for Psychiatry
Beyond the immediate clinical benefits, Cobenfy validates a new target in psychiatry. If muscarinic modulation proves effective for schizophrenia, it opens research pathways for other conditions, including bipolar disorder, Alzheimer's-related psychosis, and treatment-resistant depression.
For a field that has relied on the same fundamental mechanism since the 1950s, that is a significant development.
At PlusVirtual, we stay current with pharmaceutical developments to help our patients understand their options. If you have questions about schizophrenia treatment or any new medication, our pharmacy team is here to help.